Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk

Dow Jones

2025/05/30

0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. "We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions," Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

May 30, 2025 02:32 ET (06:32 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539210008"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539210008\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539210008?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-30 14:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539210008","market":"hk","top_or_hot":-1,"title":"Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon's First FDA Approval Since Listing Is Positive, But Expected -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-30 14:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 30, 2025 02:32 ET (06:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALC","symbol_name":"Alcon Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2539210008","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539210008","pubTimestamp":1748586720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALC":"Alcon Inc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4198":"医疗保健用品","BK4534":"瑞士信贷持仓"},"translate_title":"爱尔康自上市以来首次获得FDA批准是积极的，但在意料之中——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC":0.9},"content_text":"0632 GMT - News that Swiss eyecare specialist Alcon received its first U.S. Food and Drug Administration approval since its listing in 2019 is slightly positive, but comes as little surprise, Vontobel's Sibylle Bischofberger says in a research note. The drug, Tryptyr, was approved to treat the signs and symptoms of dry eye disease, a condition that affects around 38 million people in the U.S. and for which there is a need for new treatment options, the analyst says. \"We expect Alcon to continue performing well, especially with the launch of several products in 2025. However, results may remain somewhat volatile due to challenging market conditions,\" Vontobel says. Zurich-listed shares closed 1.95% lower Wednesday at 70.56 Swiss francs, with markets in Switzerland closed Thursday due to a holiday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 30, 2025 02:32 ET (06:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}